Multiple large-scale clinical studies and retrospective cohort analyses comparing generic and brand-name clopidogrel have found no significant differences in their adverse effect profiles, such as bleeding risks or major adverse events.
The claim states that generic and original brand-name clopidogrel have different adverse effect profiles. Papers [4], [5], and [7] directly examine this specific comparison for clopidogrel and conclude that there are no significant differences in safety profiles or adverse events (such as bleeding) between the generic and brand-name formulations. Therefore, the evidence clearly refutes the claim.